Roche ends AC Immune partnership for Alzheimer’s drugs

seekingalpha01-22

Swiss biotech AC Immune (NASDAQ:ACIU) traded lower premarket Monday after announcing that Roche (OTCQX:RHHBY) and its subsidiary Genentech have terminated their collaboration agreements for Alzheimer’...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2405903906?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215895118/image_1215895118.jpg","is_english":true,"pubTime":"2024-01-22 21:52","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2405903906","market":"us","top_or_hot":-1,"title":"Roche ends AC Immune partnership for Alzheimer’s drugs","media":"seekingalpha","content":"<div>\n<p>Swiss biotech AC Immune (NASDAQ:ACIU) traded lower premarket Monday after announcing that Roche (OTCQX:RHHBY) and its subsidiary Genentech have terminated their collaboration agreements for Alzheimer’...</p>\n\n<a href=\"https://seekingalpha.com/news/4056815-ac-immune-stock-slips-roche-ends-alzheimers-deal\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche ends AC Immune partnership for Alzheimer’s drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche ends AC Immune partnership for Alzheimer’s drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-22 21:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4056815-ac-immune-stock-slips-roche-ends-alzheimers-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss biotech AC Immune (NASDAQ:ACIU) traded lower premarket Monday after announcing that Roche (OTCQX:RHHBY) and its subsidiary Genentech have terminated their collaboration agreements for Alzheimer’...</p>\n\n<a href=\"https://seekingalpha.com/news/4056815-ac-immune-stock-slips-roche-ends-alzheimers-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AC","symbol_name":"Associated Capital Group, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4056815-ac-immune-stock-slips-roche-ends-alzheimers-deal","article_id":"2405903906","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215895118/image_1215895118.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2405903906","pubTimestamp":1705931541,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Swiss biotech AC Immune  traded lower premarket Monday after announcing that Roche  and its subsidiary Genentech have terminated their collaboration agreements for Alzheimer’s disease candidates crenezumab and semorinemab. The two monoclonal antibodies have undergone multiple clinical trials, and as the Swiss pharma giant ends its partnership, AC Immune  will regain their global rights.  Semorinemab is an anti-Tau antibody, and crenezumab functions as an anti-amyloid beta antibody. In June 2012, AC Immune  collaborated with Genentech to commercialize its anti-Tau antibodies as immunotherapeutics in a deal worth more than CHF 400M . However, the CEO of AC Immune , Andrea Pfeifer, noted that her company remains well-capitalized into 2026, thanks to a recent milestone payment related to the Tau-related immunotherapy program and $50M in financing secured in December.    More on AC Immune  AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune issues updates on Phase 2 ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AC":"Associated Capital Group, Inc.","BK4139":"生物科技","03165":"华夏欧优股对冲","BK4007":"制药","BK4135":"资产管理与托管银行","RHHBY":"罗氏控股","ACIU":"AC Immune SA"},"translate_title":"罗氏终止阿尔茨海默病药物的AC免疫合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AC":1,"ACIU":1,"RHHBY":1,"03165":0.6},"content_text":"Swiss biotech AC Immune (NASDAQ:ACIU) traded lower premarket Monday after announcing that Roche (OTCQX:RHHBY) and its subsidiary Genentech have terminated their collaboration agreements for Alzheimer’s disease candidates crenezumab and semorinemab. The two monoclonal antibodies have undergone multiple clinical trials, and as the Swiss pharma giant ends its partnership, AC Immune (ACIU) will regain their global rights.  Semorinemab is an anti-Tau antibody, and crenezumab functions as an anti-amyloid beta antibody. In June 2012, AC Immune (ACIU) collaborated with Genentech to commercialize its anti-Tau antibodies as immunotherapeutics in a deal worth more than CHF 400M (~$461M). However, the CEO of AC Immune (ACIU), Andrea Pfeifer, noted that her company remains well-capitalized into 2026, thanks to a recent milestone payment related to the Tau-related immunotherapy program and $50M in financing secured in December.    More on AC Immune  AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune issues updates on Phase 2 studies, cash runway AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2405903906"}